Obesity Market Across 7 Key Regions Projected to Hit USD 76.6 million by 2035, Report by IMARC Group

The obesity market size reached USD 17.1 million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 76.6 million by 2035, exhibiting a growth rate (CAGR) of 14.62% during 2025-2035.

The obesity market is rapidly expanding due to rising global prevalence, increasing health awareness, and growing demand for effective treatments. Obesity is a complex health condition characterized by excess body fat that increases the risk of numerous diseases, including diabetes, cardiovascular disorders, and certain cancers. As lifestyle habits continue to shift and sedentary behavior becomes more common, obesity has become one of the most urgent global health challenges.

In 2025, the market is being shaped by a strong focus on innovation in both pharmacological and non-pharmacological solutions. More people are actively seeking help to manage weight due to greater awareness of the health risks associated with obesity. At the same time, healthcare providers and policymakers are prioritizing early intervention, lifestyle changes, and long-term management strategies, which are all contributing to a growing market for obesity-related treatments and services.

One of the most significant trends in the obesity market is the launch of new anti-obesity drugs with better safety and efficacy profiles. Recent developments with GLP-1 receptor agonists have been highly promising in terms of inducing weight loss with concomitant benefits for metabolic health. These medications function by lowering appetite, decelerating digestion, and enhancing blood sugar control. In 2025, newer generations of these medications are providing more convenient dosing regimens and improved outcomes, becoming more accessible and desirable to patients.

The other significant trend is the convergence of digital health technologies to aid in weight management. Digital apps, wearables, and telehealth systems are increasingly being utilized to track physical activity, monitor nutrition, and offer real-time guidance. These applications are keeping patients engaged and motivated about their treatment regimen and enabling healthcare providers to deliver tailored care remotely. The application of artificial intelligence in interpreting patient data is also improving treatment accuracy and forecasting weight loss outcomes.

Aside from technology and medications, surgical procedures like bariatric surgery remain a vital option for those with extreme obesity. Minimally invasive procedures in 2025 are becoming more efficient and safer with shorter recovery and improved long-term results. But the trend now is shifting toward integrating surgery with lifestyle and behavior therapy to allow for long-term weight loss.

There also comes a focus on preventive healthcare and public health programs. Governments and health groups are fostering awareness campaigns, having school nutrition programs, and promoting physical activity among communities to decrease obesity rates. These are all necessary steps in stopping the increase of obesity in younger groups and developing long-term change.

The obesity market of 2025 is a pivot from short-term fixes to sustained, personalized, and holistic treatment. With more investment in research, improved accessibility to treatments, and increased society support, the journey towards avoiding and managing obesity is becoming inclusive and effective.

Emerging Therapies in Obesity Market

AMG-133 (Maridebart cafraglutide): Amgen

AMG-133 (Maridebart cafraglutide) is an investigational antibody-peptide conjugate developed by Amgen for the treatment of obesity. It combines the effects of glucagon-like peptide-1 (GLP-1) receptor activation and glucose-dependent insulinotropic polypeptide receptor antagonism to promote weight loss. Administered via subcutaneous injection, it is designed to enhance insulin secretion, reduce appetite, and slow gastric emptying, with the potential for sustained weight reduction in individuals with obesity or overweight.

CT 388: Carmot Therapeutics

CT-388 is an investigational dual GLP-1 and GIP receptor agonist developed by Carmot Therapeutics for the treatment of obesity. It aims to improve glycemic control, enhance weight loss, and reduce appetite by targeting both receptors involved in energy regulation. The drug is designed to stimulate insulin secretion while increasing energy expenditure and fat utilization, offering a promising approach to addressing obesity-related metabolic disorders.

LY3502970 (Orforglipron): Eli Lilly and Company

LY3502970 (Orforglipron) is an investigational oral GLP-1 receptor agonist developed by Eli Lilly and Company for the treatment of obesity. It aims to provide an effective, non-injectable alternative to current weight loss treatments by enhancing insulin secretion, reducing appetite, and improving metabolic health. Orforglipron is designed to help individuals with overweight or obese achieve significant and sustainable weight loss.

Amycretin: Novo Nordisk

Amycretin, developed by Novo Nordisk, is an investigational drug designed to treat obesity. It is an unimolecular GLP-1 and amylin receptor agonist intended for once-weekly subcutaneous administration. By targeting multiple pathways involved in regulating hunger and metabolism, amycretin aims to promote significant weight loss and improve metabolic health in individuals with overweight or obese patients.

Other Reports by IMARC Group:

Chronic Constipation Market https://www.openpr.com/news/3963102/chronic-constipation-market-across-7-major-regions-set-to-grow

Atrial Flutter Market https://www.openpr.com/news/3963271/atrial-flutter-market-across-7-major-regions-projected-to-grow

Acute Respiratory Distress Syndrome Market https://www.openpr.com/news/3963422/acute-respiratory-distress-syndrome-ards-market-across-7-key

Type 2 Diabetes Market https://www.openpr.com/news/3965504/type-2-diabetes-market-across-7-key-regions-projected-to-hit-us

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.

IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.